Anti-AFG3L2 antibody - N-terminal (ab171617)


  • Product name
    Anti-AFG3L2 antibody - N-terminal
    See all AFG3L2 primary antibodies
  • Description
    Rabbit polyclonal to AFG3L2 - N-terminal
  • Host species
  • Tested applications
    Suitable for: IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Cow
  • Immunogen

    Synthetic peptide within Human AFG3L2 aa 51-80 (N terminal) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary.
    Database link: Q9Y4W6

  • Positive control
    • MDA-MB453, MCF-7 and Jurkat cell line lysates. Human cerebellum tissue.



Our Abpromise guarantee covers the use of ab171617 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/10 - 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/100 - 1/500. Predicted molecular weight: 89 kDa.


  • Function
    ATP-dependent protease which is essential for axonal development.
  • Tissue specificity
    Ubiquitous. Highly expressed in the cerebellar Purkinje cells.
  • Involvement in disease
    Defects in AFG3L2 are the cause of spinocerebellar ataxia type 28 (SCA28) [MIM:610246]. It is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment.
    Defects in AFG3L2 are the cause of spastic ataxia autosomal recessive type 5 (SPAX5) [MIM:614487]. A neurodegenerative disorder characterized by early onset spasticity, peripheral neuropathy, ptosis, oculomotor apraxia, dystonia, cerebellar atrophy, and progressive myoclonic epilepsy.
  • Sequence similarities
    In the N-terminal section; belongs to the AAA ATPase family.
    In the C-terminal section; belongs to the peptidase M41 family.
  • Cellular localization
    Mitochondrion membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AFG3 (ATPase family gene 3, yeast) like 2 antibody
    • AFG3 ATPase family gene 3 like 2 (yeast) antibody
    • AFG3 ATPase family gene 3 like 2 antibody
    • AFG3 like protein 2 antibody
    • AFG3-like protein 2 antibody
    • AFG32_HUMAN antibody
    • AFG3L2 antibody
    • ATPase family gene 3 like 2 antibody
    • ATPase family gene 3 yeast antibody
    • EC 3.4.24.- antibody
    • FLJ25993 antibody
    • Paraplegin like protein antibody
    • Paraplegin-like protein antibody
    • SCA28 antibody
    • Spinocerebellar ataxia 28 antibody
    see all


  • Immunohistochemical analysis of formalin fixed and paraffin embedded Human cerebellum tissue labeling AFG3L2 with ab171617 at 1/10 dilution, followed by peroxidase conjugation of the secondary antibody and DAB staining.

  • All lanes : Anti-AFG3L2 antibody - N-terminal (ab171617) at 1/100 dilution

    Lane 1 : MDA-MB453 cell line lysate
    Lane 2 : MCF-7 cell line lysate
    Lane 3 : Jurkat cell line lysate

    Lysates/proteins at 35 µg per lane.

    Developed using the ECL technique.

    Predicted band size: 89 kDa


ab171617 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab171617.
Please use the links above to contact us or submit feedback about this product.


Sign up